公司資料
BioNTech 股價、新聞與催化劑
- 股票代碼:
- BNTX
- 交易所:
- NASDAQ
- 產業:
- Nucleic Acid Drugs
- 所在地:
- Mainz, Germany
股票表現
91.60 USD (-1.60%)
收盤價
最後更新: 2026年8月17日
22.5B USD
市值
股價為何變動
As of Aug 17, 2026, BNTX closed down 1.60% at $91.60. No new same-company headline was identified in the current news window.
公司概覽
Next-Generation Biopharmaceutical Platform
BioNTech develops medicines for cancer and other serious diseases using complementary immunotherapy and vaccine technologies. Its current oncology strategy integrates checkpoint and angiogenesis modulation, antibody-drug conjugates and mRNA cancer immunotherapies across multiple tumor types.
Pumitamig
Pumitamig, also known as BNT327 or BMS986545, is a bispecific immunomodulator that combines PD-L1 checkpoint inhibition with VEGF-A neutralization. BioNTech and Bristol Myers Squibb are evaluating it in a broad pivotal program spanning lung, breast, colorectal, gastric and other solid tumors.
Gotistobart
Gotistobart is a tumor-microenvironment-selective CTLA-4 antibody designed to deplete regulatory T cells. The Phase 3 PRESERVE-003 trial is evaluating it in metastatic squamous non-small cell lung cancer after platinum chemotherapy and PD-(L)1 treatment.
HER2-Targeted ADC
Trastuzumab pamirtecan is a HER2-targeted antibody-drug conjugate partnered with DualityBio. It is being developed in recurrent endometrial cancer and HER2-low metastatic breast cancer through potentially registrational cohorts and Phase 3 trials.
B7H3-Targeted ADC
BNT324, or DB-1311, is a B7H3-targeted antibody-drug conjugate with clinical activity under evaluation in prostate, cervical and ovarian cancers. A Phase 3 trial against docetaxel in metastatic castration-resistant prostate cancer is planned.
Infectious-Disease Vaccines
BioNTech’s commercial vaccine business remains anchored by its COVID-19 collaboration with Pfizer. The partners continue to adapt the vaccine to circulating variants and prepare for seasonal regulatory approvals and supply.
未來催化劑
- Phase 2 data from the ROSETTA Lung-02 pumitamig trial at ASCO on May 29–June 2, 2026.
- Multiple pumitamig combination readouts expected during 2026.
- Interim pivotal-stage data from the Phase 3 PRESERVE-003 gotistobart trial expected in 2026.
- BLA submission for trastuzumab pamirtecan in endometrial cancer planned in 2026, subject to regulatory feedback.
- Phase 3 DYNASTY-Breast02 data for trastuzumab pamirtecan expected in 2026.
- Initiation of the Phase 3 BNT324 trial in metastatic castration-resistant prostate cancer expected in 2026.
- Potential launch of a variant-adapted COVID-19 vaccine ahead of the 2026/2027 vaccination season, pending approval.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。